Cabozantinib After Progression Improves Survival in Advanced Renal Cell Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Cabozantinib beyond progression improves survival in advanced renal cell carcinoma patients: the CABEYOND study (Meet-URO 21)
Expert Rev Anticancer Ther 2021 Nov 05;[EPub Ahead of Print], A Mennitto, E Zattarin, M Di Maio, D Bimbatti, U De Giorgi, S Buti, D Santini, C Casadei, M Sorarù, C Messina, C Mucciarini, G Di Lorenzo, G Roviello, C Buttigliero, M Stellato, P Sepe, M Claps, V Guadalupi, A Ottini, S Pignata, FG De Braud, E Verzoni, G ProcopioFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.